文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

地塞米松是剂量依赖性药物相互作用的主要肇事者:对HIV感染者使用的意义

Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

地塞米松在COVID-19中的广泛使用暴露出对其药物相互作用潜力认识不足,尤其是与抗逆转录病毒药物的相互作用。地塞米松既是CYP3A4的底物又是剂量依赖性诱导剂,而许多抗逆转录病毒药物是CYP3A4的底物和/或抑制剂或诱导剂,因此存在地塞米松作为肇事者或受害者的相互作用担忧。本文总结地塞米松相互作用潜力的体外和体内数据,并考虑不同地塞米松剂量和治疗持续时间,提出与抗逆转录病毒药物相互作用的管理建议。

要点

  • 地塞米松是CYP3A4的底物和剂量依赖性诱导剂,与抗逆转录病毒药物存在双向相互作用风险。
  • 地塞米松日剂量范围一般为0.5至40 mg,疗程可短可长或间歇,使相互作用评估复杂。
  • 地塞米松的相互作用仅对有限数量药物进行过评估。

核心结论

  • 地塞米松是剂量依赖性CYP3A4诱导剂和底物,与抗逆转录病毒药物合用时需考虑其作为肇事者或受害者的药物相互作用。

研究设计与样本

  • 本文总结地塞米松相互作用潜力的可用体外和体内数据,并提出与抗逆转录病毒药物相互作用的管理建议。

主要发现

  • 地塞米松日剂量一般为0.5至40 mg,治疗疗程可短、可长或间歇。
  • 地塞米松的相互作用仅对有限数量药物进行过评估。

局限性

  • 地塞米松的相互作用仅对有限数量药物进行过评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Global use of dexamethasone in COVID-19 patients has revealed a poor understanding of the drug-drug interaction (DDI) potential of dexamethasone, particularly with antiretroviral agents (ARVs). Dexamethasone is both a substrate and a dose-dependent inducer of cytochrome P450 3A4 (CYP3A4). As many ARVs are substrates and/or inhibitors or inducers of CYP3A4, there is concern about DDIs with dexamethasone either as a perpetrator or a victim. Assessment of DDIs that involve dexamethasone is complex as dexamethasone is used at a range of daily doses (generally 0.5 up to 40 mg) and a treatment course can be short, long, or intermittent. Moreover, DDIs with dexamethasone have been evaluated only for a limited number of drugs. Here, we summarize the available in vitro and in vivo data on the interaction potential of dexamethasone and provide recommendations for the management of DDIs with ARVs, considering various dexamethasone dosages and treatment durations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Jacobs TG, Marzolini C, Back DJ, et al. Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV. J Antimicrob Chemother. 2022. PMID: 34791318. doi:10.1093/jac/dkab412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。